NO180417C - Syrelabile linkermolekyler - Google Patents
Syrelabile linkermolekylerInfo
- Publication number
- NO180417C NO180417C NO920040A NO920040A NO180417C NO 180417 C NO180417 C NO 180417C NO 920040 A NO920040 A NO 920040A NO 920040 A NO920040 A NO 920040A NO 180417 C NO180417 C NO 180417C
- Authority
- NO
- Norway
- Prior art keywords
- aralkyl
- aryl
- lower alkyl
- acid
- alkylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90203526 | 1990-12-31 |
Publications (4)
Publication Number | Publication Date |
---|---|
NO920040D0 NO920040D0 (no) | 1992-01-02 |
NO920040L NO920040L (no) | 1992-07-01 |
NO180417B NO180417B (no) | 1997-01-06 |
NO180417C true NO180417C (no) | 1997-04-16 |
Family
ID=8205218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO920040A NO180417C (no) | 1990-12-31 | 1992-01-02 | Syrelabile linkermolekyler |
Country Status (17)
Country | Link |
---|---|
US (1) | US5306809A (fr) |
EP (1) | EP0495265B1 (fr) |
JP (1) | JPH04334377A (fr) |
KR (1) | KR920012063A (fr) |
AT (1) | ATE109476T1 (fr) |
AU (1) | AU646121B2 (fr) |
CA (1) | CA2058595A1 (fr) |
DE (1) | DE69103255T2 (fr) |
DK (1) | DK0495265T3 (fr) |
ES (1) | ES2061166T3 (fr) |
FI (1) | FI101678B1 (fr) |
HU (1) | HUT60484A (fr) |
IE (1) | IE65406B1 (fr) |
NO (1) | NO180417C (fr) |
NZ (1) | NZ241217A (fr) |
PT (1) | PT99954B (fr) |
ZA (1) | ZA9110203B (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5505931A (en) * | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
EP0638583A1 (fr) * | 1993-08-13 | 1995-02-15 | Hoechst Aktiengesellschaft | Aminosucre substances actives, un procédé pour leur préparation, et leur utilisation comme médicaments |
DE4433890C2 (de) * | 1994-09-22 | 1999-02-18 | Deutsches Krebsforsch | Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein |
WO1997023243A1 (fr) * | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Segments de liaison hydrazone ramifies |
DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
US6800616B2 (en) | 1998-02-26 | 2004-10-05 | Supergen, Inc. | Treatment of HIV infections |
CA2248592A1 (fr) | 1998-08-31 | 2000-02-29 | Christopher D. Batich | Microspheres pour le traitement du cancer |
US6140015A (en) * | 1998-12-10 | 2000-10-31 | International Business Machines Corporation | Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching |
TWI242000B (en) * | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
CN1149219C (zh) * | 1999-03-11 | 2004-05-12 | 阿登尼亚投资有限公司 | 治疗癌症的新化合物 |
US6706892B1 (en) * | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
BRPI0003386B8 (pt) * | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas |
MXPA03003401A (es) * | 2000-10-16 | 2004-06-30 | Neopharm Inc | Formulacion liposomica de mitoxantrona. |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
DK2163256T3 (en) | 2001-05-11 | 2015-12-07 | Ludwig Inst For Cancer Res Ltd | Specific binding proteins and use thereof |
GB0116143D0 (en) * | 2001-07-02 | 2001-08-22 | Amersham Pharm Biotech Uk Ltd | Chemical capture reagent |
KR100507968B1 (ko) * | 2001-08-18 | 2005-08-17 | 한국과학기술연구원 | 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법 |
WO2003051113A1 (fr) * | 2001-12-14 | 2003-06-26 | The University Of Wyoming | Methodes et compositions de liberation controlee de medicaments |
US8361464B2 (en) | 2002-03-01 | 2013-01-29 | Immunomedics, Inc. | Anthracycline-Antibody Conjugates for Cancer Therapy |
CA2478522A1 (fr) * | 2002-03-08 | 2003-09-18 | Emory University | Nouvelles constructions de facteurs viia de curcuminoides utilisees en tant que suppresseurs de la croissance tumorale et de l'angiogenese |
US20050069551A1 (en) * | 2002-03-08 | 2005-03-31 | Emory University | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis |
EP1506218B1 (fr) * | 2002-05-24 | 2017-04-12 | Arrowhead Pharmaceuticals, Inc. | Modification reversible de l'interaction membranaire |
CN1733314A (zh) * | 2004-08-11 | 2006-02-15 | 张阳德 | 半乳糖化白蛋白磁性阿霉素纳米粒的制备方法 |
US20060135459A1 (en) * | 2004-11-09 | 2006-06-22 | Epstein Alan L | Targeted innate immunity |
NZ556788A (en) | 2005-01-05 | 2011-03-31 | Biogen Idec Inc | Humanized CRIPTO binding molecules with CDRs from murine B3F6 |
EP2083866A4 (fr) | 2006-10-27 | 2011-12-28 | Wei-Chiang Shen | Interféron lipidisé et ses utilisations |
JP5276017B2 (ja) * | 2007-01-25 | 2013-08-28 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfr変異体仲介性疾患の治療における抗egfr抗体の使用 |
CN101688229B (zh) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
MX2010001757A (es) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. |
US8618096B2 (en) * | 2008-07-21 | 2013-12-31 | The Regents Of The University Of California | Prodrug compositions and methods for using the same in treating cancer and malaria |
JP5472288B2 (ja) * | 2009-03-17 | 2014-04-16 | 国立大学法人 東京大学 | タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体 |
US8535948B2 (en) * | 2009-03-26 | 2013-09-17 | Institute For Systems Biology | Method to determine protein interaction sites |
EP2448966B1 (fr) | 2009-07-03 | 2018-11-14 | Avipep Pty Ltd | Immunoconjugués et leurs procédés de production |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
SG181814A1 (en) | 2009-12-23 | 2012-07-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
RU2013103763A (ru) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения |
WO2013012733A1 (fr) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées |
CA2845391C (fr) | 2011-08-18 | 2021-01-19 | Affinity Biosciences Pty Ltd | Polypeptides solubles |
JP6247226B2 (ja) | 2012-01-10 | 2017-12-13 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 血液脳関門を越える治療分子の輸送の向上 |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
WO2014057436A2 (fr) | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Conjugué anticancéreux |
WO2014124227A1 (fr) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Forme de pro-médicament (p2pdox) de la 2-pyrrolinodoxorubicine fortement puissante conjuguée à des anticorps pour la thérapie ciblée du cancer |
WO2014141094A1 (fr) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Conjugué anticancéreux |
WO2015123595A1 (fr) | 2014-02-14 | 2015-08-20 | The Regents Of The University Of California | Peroxydes cycliques utilisés en tant que promédicaments pour l'administration sélective d'agents |
SG11201702627UA (en) | 2014-10-03 | 2017-04-27 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
EA034582B1 (ru) | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
WO2017088058A1 (fr) | 2015-11-24 | 2017-06-01 | Transfert Plus, S.E.C. | Composés peptidiques et conjugués peptidiques destinés au traitement du cancer par chimiothérapie à médiation par un récepteur |
WO2018118015A1 (fr) | 2016-12-19 | 2018-06-28 | Morehouse School Of Medicine | Compositions et procédés pour traiter des maladies par inhibition de libération d'exosomes |
US10800817B2 (en) | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
WO2020243338A1 (fr) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire |
US11180534B1 (en) | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
WO2023137443A1 (fr) * | 2022-01-14 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | Dérivés de verrucarine a et conjugués anticorps-médicament de ceux-ci |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631190A (en) * | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4744981A (en) * | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
US5140013A (en) * | 1989-11-28 | 1992-08-18 | Universite Laval | Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers |
-
1991
- 1991-12-27 FI FI916131A patent/FI101678B1/fi active
- 1991-12-27 JP JP3361486A patent/JPH04334377A/ja active Pending
- 1991-12-28 HU HU914133A patent/HUT60484A/hu unknown
- 1991-12-30 IE IE456791A patent/IE65406B1/en not_active IP Right Cessation
- 1991-12-30 KR KR1019910025982A patent/KR920012063A/ko not_active Application Discontinuation
- 1991-12-30 DK DK91203439.4T patent/DK0495265T3/da active
- 1991-12-30 ES ES91203439T patent/ES2061166T3/es not_active Expired - Lifetime
- 1991-12-30 EP EP91203439A patent/EP0495265B1/fr not_active Expired - Lifetime
- 1991-12-30 AU AU90098/91A patent/AU646121B2/en not_active Ceased
- 1991-12-30 AT AT91203439T patent/ATE109476T1/de active
- 1991-12-30 ZA ZA9110203A patent/ZA9110203B/xx unknown
- 1991-12-30 DE DE69103255T patent/DE69103255T2/de not_active Expired - Fee Related
- 1991-12-30 CA CA002058595A patent/CA2058595A1/fr not_active Abandoned
- 1991-12-30 PT PT99954A patent/PT99954B/pt not_active IP Right Cessation
- 1991-12-31 US US07/815,671 patent/US5306809A/en not_active Expired - Fee Related
-
1992
- 1992-01-02 NO NO920040A patent/NO180417C/no unknown
- 1992-01-06 NZ NZ241217A patent/NZ241217A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE69103255T2 (de) | 1994-12-08 |
PT99954A (pt) | 1993-06-30 |
ATE109476T1 (de) | 1994-08-15 |
FI916131A (fi) | 1992-07-01 |
NO180417B (no) | 1997-01-06 |
PT99954B (pt) | 1999-06-30 |
NZ241217A (en) | 1993-12-23 |
IE65406B1 (en) | 1995-10-18 |
JPH04334377A (ja) | 1992-11-20 |
DK0495265T3 (da) | 1995-01-02 |
CA2058595A1 (fr) | 1992-07-01 |
IE914567A1 (en) | 1992-07-01 |
HU914133D0 (en) | 1992-03-30 |
NO920040L (no) | 1992-07-01 |
US5306809A (en) | 1994-04-26 |
FI916131A0 (fi) | 1991-12-27 |
AU646121B2 (en) | 1994-02-10 |
EP0495265A1 (fr) | 1992-07-22 |
EP0495265B1 (fr) | 1994-08-03 |
FI101678B (fi) | 1998-08-14 |
HUT60484A (en) | 1992-09-28 |
FI101678B1 (fi) | 1998-08-14 |
DE69103255D1 (de) | 1994-09-08 |
KR920012063A (ko) | 1992-07-25 |
ES2061166T3 (es) | 1994-12-01 |
AU9009891A (en) | 1993-01-28 |
ZA9110203B (en) | 1993-01-27 |
NO920040D0 (no) | 1992-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO180417C (no) | Syrelabile linkermolekyler | |
US4880935A (en) | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates | |
MXPA03010432A (es) | Inmunoconjugados del anticuerpo cd44 citotoxico. | |
ATE294592T1 (de) | Thioether enthaltende konjugate | |
FI912285A0 (fi) | Nya bifunktionella kopplingsfoereningar, konjugat och foerfaranden foer framstaellning av dessa. | |
US4263279A (en) | Pharmaceutically active compositions containing adriamycin and daunomycin | |
IL64722A0 (en) | Immunoglobin conjugates,their preparation and pharmaceutical compositions containing them | |
DK0384769T3 (da) | Mærkning af proteiner | |
HU184736B (en) | Process for preparing anticarcinogenic immunoglobuline derivatives | |
KR920012106A (ko) | 표지된 변형 올리고뉴클레오티드 | |
FI891098A (fi) | Magnetiska proteinkonjugater, foerfarande foer deras framstaellning och deras anvaendning. | |
WO2004041307A3 (fr) | Compositions et procedes de traitement de cancer au moyen d'immunoconjugues d'anticorps cytotoxique cd44 et radiotherapie | |
WO1996040664A3 (fr) | Preparations d'immunogenes et d'autres conjugues de medicaments | |
HUT70481A (en) | Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them | |
TH17541A (th) | สารประกอบเฮเทอโรไซคลิค |